PPAR-δ agonist

Seladelpar

Brand names: Livdelzi

Seladelpar is a PPAR-delta agonist used for primary biliary cholangitis, typically in combination with or as an alternative to ursodeoxycholic acid in adults with an inadequate response or intolerance.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

By activating peroxisome proliferator-activated receptor delta, it reduces hepatic bile acid synthesis and exerts anti-cholestatic and anti-inflammatory effects.

Prescribing in practice

It should not be used in patients with decompensated cirrhosis, and liver biochemistry must be assessed before and during treatment because of the risk of hepatic adverse effects.
Myalgia and musculoskeletal effects have been reported, so investigate new or worsening muscle symptoms.
Treatment response is judged on biochemical markers of cholestasis according to the SPC and current prescribing references.

Monitoring

Monitor liver function tests at baseline and periodically during treatment, and assess biochemical response to therapy.

Counselling the patient

Attend for the blood tests needed to monitor your liver.
Report unexplained muscle pain, dark urine, or yellowing of the skin or eyes.

Evidence & guidelines

Seladelpar is a second-line treatment option for primary biliary cholangitis in patients with inadequate response to ursodeoxycholic acid.

Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Pathways